Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial

Fig. 3

FENO Least square mean change from baseline versus placebo (full analysis set). Baseline was defined separately for each treatment period as the measurement performed on day 1 of each treatment period. Error bars represent 95% confidence intervals. * p <0.01, ** p = <0.001, *** p < 0.0001 QD once daily, FENO fraction exhaled nitric oxide, ppb parts per billion, NS not significant

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us